menu
{ "item_title" : "Pharmacotherapy of Child and Adolescent Psychiatric Disorders", "item_author" : [" David R. Rosenberg", "Samuel Gershon", "Neal Ryan "], "item_description" : "This book fulfils an urgent need for an updated text on pediatricpsychopharmacology. It takes a unique approach in discussingrecent findings within the context of current issues, includingeconomic and political ones. The book covers the emergingquestion of treating children who do not yet meet diagnosticcriteria for psychosis, e.g, schizophrenia or bipolar disorder, butwho are deemed to be at high risk. This is an active area ofdebate: such children are being treated in certain centers, whileothers reject this completely. The book addresses theantidepressant controversy, the placebo response and uniquestrategies for delineating this, and ways to optimize the differential between active medication and placebo. Itreviews the impact of recent American Heart Association guidelinesfor monitoring children on stimulants and other psychotropics. Itadheres closely to DSM-IV diagnostic criteria throughout. Thebook describes the use of newly approved drugs such as Lexapro fortreating adolescent depression and the novel compoundIntuniv. It covers the TADS and CAMS studies, which evaluatedthe use of SSRIs alone and in combination with cognitive behavioraltherapy for adolescent depression. Other topics includetreatment of bipolar disorders, the increasing popularity ofgeneric equivalents, combination pharmacotherapy and the potentialdangers of psychotropic medications. Third edition of the first ever book published on pediatricpsychopharmacology from renowned editors.Incorporates current developments with regard to SSRIs, theirindications and their safety issues, including possible associatedsuicidal behavior.Addresses concerns about cardiovascular side effects of the newstimulant medications available, and compares to other FDA-approvedmedications for ADHD.Features many tables, figures and pictorials, making it highlyaccessible and reader friendly.", "item_img_path" : "https://covers2.booksamillion.com/covers/bam/0/47/097/376/0470973765_b.jpg", "price_data" : { "retail_price" : "124.95", "online_price" : "124.95", "our_price" : "124.95", "club_price" : "124.95", "savings_pct" : "0", "savings_amt" : "0.00", "club_savings_pct" : "0", "club_savings_amt" : "0.00", "discount_pct" : "10", "store_price" : "" } }
Pharmacotherapy of Child and Adolescent Psychiatric Disorders|David R. Rosenberg

Pharmacotherapy of Child and Adolescent Psychiatric Disorders

local_shippingShip to Me
In Stock.
FREE Shipping for Club Members help

Overview

This book fulfils an urgent need for an updated text on pediatricpsychopharmacology. It takes a unique approach in discussingrecent findings within the context of current issues, includingeconomic and political ones. The book covers the emergingquestion of treating children who do not yet meet diagnosticcriteria for psychosis, e.g, schizophrenia or bipolar disorder, butwho are deemed to be at high risk. This is an active area ofdebate: such children are being treated in certain centers, whileothers reject this completely. The book addresses theantidepressant controversy, the placebo response and uniquestrategies for delineating this, and ways to optimize the differential between active medication and placebo. Itreviews the impact of recent American Heart Association guidelinesfor monitoring children on stimulants and other psychotropics. Itadheres closely to DSM-IV diagnostic criteria throughout. Thebook describes the use of newly approved drugs such as Lexapro fortreating adolescent depression and the novel compoundIntuniv. It covers the TADS and CAMS studies, which evaluatedthe use of SSRIs alone and in combination with cognitive behavioraltherapy for adolescent depression. Other topics includetreatment of bipolar disorders, the increasing popularity ofgeneric equivalents, combination pharmacotherapy and the potentialdangers of psychotropic medications.

  • Third edition of the first ever book published on pediatricpsychopharmacology from renowned editors.
  • Incorporates current developments with regard to SSRIs, theirindications and their safety issues, including possible associatedsuicidal behavior.
  • Addresses concerns about cardiovascular side effects of the newstimulant medications available, and compares to other FDA-approvedmedications for ADHD.
  • Features many tables, figures and pictorials, making it highlyaccessible and reader friendly.

This item is Non-Returnable

Details

  • ISBN-13: 9780470973769
  • ISBN-10: 0470973765
  • Publisher: John Wiley & Sons
  • Publish Date: February 2012
  • Dimensions: 9.9 x 6.9 x 1 inches
  • Shipping Weight: 1.9 pounds
  • Page Count: 480

Related Categories

You May Also Like...

    1

BAM Customer Reviews